The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study

• DOI: 10.1111/jcpt.12211
• Publication Date: 2014-09-24T12:09:24Z
• Authors: R. Chen; Y. Zhang; S. Tang; X. Lv; S. Wu; F. Sun; Y. Xia; S. Y. Zhan
• Keywords: HLA-DQB1

What is known and objective Research on genetic factors associated with antitubercular drug-induced liver injuries (ATLI) has been reported. However, most of the research focused polymorphisms genes encoding metabolic enzymes, including NAT2, GST CYP450. It probable that immune system also contributes to onset drug adverse effects. A few small studies have explored possible association HLA (DILI), but more supportive evidence from larger or prospective cohort designs needed. We aim explore HLA-DQB1 gene ATLI in a case–control study. Methods study design was used. recorded prospectively followed-up patients receiving antituberculosis treatment. Identified cases were matched control tuberculosis within same no effects 1 : ratio. used sequence-based typing method determine genotypes. Odds ratios (OR) 95% confidence intervals (CI) calculated using conditional logistic regression. Results discussion Eighty-nine included this successful for 177 subjects. No between frequency genotypes statistically significant univariate analyses. Multivariate analysis regression model revealed individuals two DQB1*05 alleles at higher risk than The OR 5·28 adjusted use protective drugs weight (10/88 VS 2/88, CI: 1·134-24·615, P = 0·034). Analysis according injury type showed both mixed cholestatic/mixed had proportions 02 (P values 0·028 0·005, respectively). new conclusion This suggests likely subjects HLA-DQB1*05/*05 genotype. Further are needed verify association.